Trastuzumab Deruxtecan
Idiopathic Pulmonary Fibrosis
Clinical trials
1
Developer
AstraZeneca
Overview
Trastuzumab Deruxtecan is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 1 tracked IPF clinical trial.
Trastuzumab Deruxtecan clinical trials
Explore related
Medical disclaimer. This page summarizes research about Trastuzumab Deruxtecan for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.